AI CuratorAI-generated
Research summary · AI summary · not yet reviewedHuman studyPhase 3Trial registry
Human Study on Ublituximab Administration Routes in Relapsing Multiple Sclerosis
A Phase 3 study is investigating how the drug ublituximab behaves in the body when given subcutaneously compared to intravenous administration in people with Relapsing Multiple Sclerosis. The study includes a randomized design and has a follow-up period of up to 120 weeks.
- Tags
- #MSResearch
- Most relevant to
- —
- Source
- Read original source
This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.
Why it matters
Understanding the pharmacokinetics of ublituximab may help optimize its administration for better patient outcomes, though no results have yet been reported.
What this does not prove
The study's results are currently not available, and planned enrollment and endpoints are not findings themselves.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Interventional
- Participants / samples
- Not reported
- Randomised
- Yes
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- RRMS
- Publication date
- Not reported
- Evidence reviewed
- Trial registry record
- Regulatory approval
- Not reported
- Research areas
- Not classified
Original sources
Supporting passages (11)
study phaseThis is a Phase 3, open label, parallel-group, multicenter study in participants with RMS.
study designThis is a Phase 3, open label, parallel-group, multicenter study in participants with RMS.
subjects"briefSummary": "The purpose of this study is to assess the pharmacokinetics of ublituximab when administered subcutaneously (SC) compared to intravenous (IV) administration in participants with RMS.",
randomized"allocation": "RANDOMIZED"
peer reviewedNo results are posted.
relevant ms types"conditions": [ "Relapsing Multiple Sclerosis" ]
intervention"Biological: Ublituximab"
primary endpoint"measure": "Area Under the Curve From Week 0 to Week 24 (AUC0-W24) of Ublituximab"
follow up"timeFrame": "Up to Week 120"
findings"briefSummary": "The purpose of this study is to assess the pharmacokinetics of ublituximab when administered subcutaneously (SC) compared to intravenous (IV) administration in participants with RMS.",
limitationsNo results are posted. Planned enrolment and endpoints are not findings.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.